Those successes, as well as CDK4/6 and MEK hyperactivation in patient MPNSTs, propelled our examination of combined CDK4/6 and MEK inhibition in our de novo MPNST model [14]. The gene discussed is CDK4; the disease is malignant peripheral nerve sheath tumor.